Images List Premium Download Classic

Arteriosclerosis

Arteriosclerosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 28, 2017 - N°20170275378

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 14, 2017 - N°20170260290

Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, ...
Los Angeles Biomedical Research Institute At Harbor- Ucla Medical Center
August 24, 2017 - N°20170239257

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic ...
Arteriosclerosis Patent Pack
Download + patent application PDFs
Arteriosclerosis Patent Applications
Download + Arteriosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Arteriosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 13, 2017 - N°20170198253

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Cardiovascular disease treatment and prevention
Transdermal Biotechnology, Inc.
July 13, 2017 - N°20170196981

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the ...
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 13, 2017 - N°20170196858

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Arteriosclerosis Patent Pack
Download + patent application PDFs
Arteriosclerosis Patent Applications
Download + Arteriosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Arteriosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pyridine derivative
Teijin Pharma Limited
July 06, 2017 - N°20170190694

Provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, ...
Use of beta-nicotinamide mononucleotide in preparation of health-care products for preventing and treating arteriosclerosis and ...
Bontac Bio-engineering (shenzhen) Co., Ltd
June 15, 2017 - N°20170165283

A health care product having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing health care products for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
Use of beta-nicotinamide mononucleotide in preparation of drugs for preventing and treating arteriosclerosis and cardio-cerebrovascular ...
Bontac Bio-engineering (shenzhen) Co., Ltd.
June 15, 2017 - N°20170165282

A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
Binding inhibitor between tctp dimer type ige-dependent histamine releasing factor and receptor thereof, and use ...
Ewha University - Industry Collaboration Foundation
June 08, 2017 - N°20170158761

The present invention relates to a receptor-binding domain of an ige-dependent histamine releasing factor (hrf), and a use thereof, and more specifically, ascertains, as an hrf structual region, and a fl domain and an h2 domain which bind to a receptor of hrf existing in a cell membrane, ascertains the c-terminus domain of the hrf, and ascertains that a material ...
Pyrazine derivatives
Teijin Pharma Limited
June 01, 2017 - N°20170152242

Provided is a novel pyrazine derivative represented by the following formula (i) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which urat1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, lesch-nyhan syndrome, and the like.
Biological-information detecting apparatus, seat with backrest, and cardiopulmonary-function monitoring apparatus
University Of Tsukuba
June 01, 2017 - N°20170150929

A biological-information detecting apparatus includes a first blood-flow measuring device provided at a seat surface of a seat, the first blood-flow measuring device measuring a condition of a blood flow of a popliteal artery of a measurement subject seated in the seat, a second blood-flow measuring device provided at a back of the seat, the second blood-flow measuring device measuring ...
Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from ...
Md Healthcare Inc.
March 30, 2017 - N°20170087195

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, ...
Arteriosclerosis Patent Pack
Download + patent application PDFs
Arteriosclerosis Patent Applications
Download + Arteriosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Arteriosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pentylenetetrazole derivatives
Biomarin Pharmaceutical Inc.
February 16, 2017 - N°20170044165

Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, and r10 are as disclosed herein, or a pharmaceutically salt thereof. Pharmaceutical compositions comprising the compounds and methods of their use, for instance in treating senility, senile confusion, psychoses, psychoneuroses when anxiety and nervous tension were present, cerebral arteriosclerosis, nausea, depression, fatigue, debilitation, mild behavioral disorders, irritability, emotional instability, antisocial ...
Agent for preventing or ameliorating vascular endothelial malfunction
Kyowa Hakko Bio Co., Ltd.
February 16, 2017 - N°20170042962

An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e. G., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e. G., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle ...
5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
Daiichi Sankyo Company, Limited
December 29, 2016 - N°20160376267

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke ...
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The Johns Hopkins University
November 24, 2016 - N°20160339019

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Dna vaccine containing specific epitope of apolipoprotein (a)
Angesmg, Inc.
October 20, 2016 - N°20160303211

The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b ...
Agent for preventing or ameliorating vascular endothelial malfunction
Kyowa Hakko Bio Co., Ltd.
October 13, 2016 - N°20160296586

An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e. G., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e. G., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle ...
Continuous arycyclic compound
Mitsubishi Tanabe Pharma Corporation
September 22, 2016 - N°20160272614

This is to provide a continuous arycyclic compound having a dgat1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a dgat1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. ...
Variants of c-type natriuretic peptide
Biomarin Pharmaceutical Inc.
September 08, 2016 - N°20160256553

The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e. G., achondroplasia), and vascular smooth muscle disorders (e. G., restenosis and ...
Loading